Together this data further adds to the growing evidence that deoxynucleoside supplementation is a valid therapeutic approach for treating patients with pathogenic RRM2B variants and possible also for other forms of mitochondrial diseases caused by mtDNA depletion. The gene discussed is RRM2B; the disease is inborn mitochondrial metabolism disorder.